Improving specific productivity moves the goal beyond pumping out higher titers, but it demands a deeper understanding of cellular biology and protein expression.
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- Do's And Don'ts Of Material Handling When Retrofitting For ADCs
- Building Enterprise Resilience From QRM Signals
- Single-Use Standards Are Maturing, But The Process Remains King
- Mind The Potent Compounds When Retrofitting Facilities For ADCs
- New USP Research Shows MAM As Alternative To Conventional Methods
GUEST COLUMNISTS
-
The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
The promise of AI is colliding with the harsh reality of data chaos in pharma manufacturing. This article explores why most AI investments fail, and a 5-layer solution.
-
Why Use Total Organic Carbon Analysis For Cleaning Validation?
Total organic carbon analysis is probably the most “fit for use” analytical method to validate cleaning processes, particularly within a science- and risk-based approach.
-
Do's And Don'ts Of Material Handling When Retrofitting For ADCs
Antibody-drug conjugate manufacturing includes extremely dangerous ingredients, and most legacy facilities lack the features and flows for safe handling.
-
Building Enterprise Resilience From QRM Signals
Turn enterprise resource management (ERM) from a checklist into a true decision system — so risk informs everyday choices before quality events become supply disruptions, delays, or regulatory exposure.
-
Single-Use Standards Are Maturing, But The Process Remains King
The food industry inspired single-use in biopharma, but the regulatory landscape is far more complex. If you're worried about compliance, this discussion can help.
-
Mind The Potent Compounds When Retrofitting Facilities For ADCs
Antibody-drug conjugate manufacturing introduces significantly more risk to employees. Likewise, facility safety requirements are especially intense.
-
New USP Research Shows MAM As Alternative To Conventional Methods
Results show the multi-attribute method provided superior specificity and detected molecular modifications far better than the status quo.
BIOSIMILAR WHITE PAPERS
-
Bio-Based Polymers Towards Net Zero In Single-Use Bioprocessing
Decarbonizing healthcare and pharmaceuticals is vital to meet climate goals and safeguard public health. Learn why these energy-intensive sectors must act swiftly to reduce emissions and navigate complex global supply chains.
-
Innovation In Filtration3/18/2025
Filtration removes contaminants to ensure safety and is essential in various applications, from lab-scale tasks to GMP production. Explore how its simplicity and reliability make it indispensable.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Aseptic filling for ATMPs demands precision and sterility. Robotic gloveless isolators minimize contamination risk through automation and real-time monitoring, ensuring compliance for personalized therapies.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing5/12/2025
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Assessing A Targeted Molecular Method Against Traditional In Vitro Testing For Adventitious Virus Detection10/3/2024
Discover a CHO AOF panel that provides rapid detection of relevant adventitious viral contaminants in bulk harvest material, and explore data showing equivalent sensitivity to the in vitro assay.
-
The Evolution Of Antibody-Drug Manufacturing6/3/2024
Explore how ADC chemistry and manufacturing have evolved, the challenges this dynamic growth has created, and how CDMOs are adapting to these changes to meet customer needs, now and in the future.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Sandoz Canada Launches First Ophthalmology Biosimilar
- Alvotech Enters Supply And Commercialization Agreements For Canada And Australia & New Zealand Covering Multiple Biosimilar Candidates
- Samsung Bioepis Reaches Settlement Agreement For Eylea (Aflibercept) Biosimilar In Europe And The Rest Of The World
- Patent Settlement Secures Pathway For ADVANZ PHARMA And Alvotech To Market Eylea Biosimilar
- Alvotech Secures Settlement Agreement in Global Markets For Its Biosimilar To Eylea® 2mg
- MS Pharma Group Signs Exclusive Biosimilars Partnership Agreement With Hetero
- Brazil Achieves A Historic Milestone: Blau Farmacêutica Fully Develops One Of The World's Most Advanced Biosimilars Immunotherapies
- Over Three Dozen Groups Join The Biosimilars Council And AAM To Reiterate Support For Interchangeability Legislation
NEWSLETTER ARCHIVE
- 01.29.26 -- The Latest In Upstream HCP Mitigation
- 01.15.26 -- SUS Insufficient For 40% Of Biopharma
- 01.08.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance
- 12.18.25 -- Why Your MVP And Its Evolution Matters To Manufacturing
- 12.11.25 -- Indian Biosimilar Companies Are Poised To Succeed In The Global Market